ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет 2012 год № 1

Субклинический гипотиреоз: практические рекомендации

Симон Пирс1,2 и Салман Разви1,3
1. Институт Генетической медицины, Университет Ньюкасла, Ньюкасл Великобритания
2. Отделение эндокринологии, Больница Королевы Виктории, Ньюкасл, Великобритания
3. Отделение эндокринологии, Больница Гейтсхеда общественного фонда здравоохранения, Гейтсхед, Великобритания


Под редакцией В.В. Фадеева



Заключение

Несмотря на отсутствие достаточной доказательной базы и результатов рандомизированных клинических исследования, посвященных изучению заместительной терапии L-X4 при субклиническом гипотиреозе, за последние 4 года мы получили данные о его возможной связи с сердечно-сосудистыми заболеваниями.

Более того, установлено влияние возраста и уровня ТТГ на сердечно-сосудистый риск, подтверждена безопасность терапии L-T4, выявленная на большой когорте пациентов. Новые данные позволяют нам определить ту целевую группу пациентов с СГ, которым терапия L-T4 показана и принесет пользу.

Литература

1. Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of Hypothyroidism. Br Med J 1973; 5854: 657-662.

2. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977; 7: 481-93.

3. Hollowell JG,    Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer    CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-99.

4. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease preva-lence study. Arch Intern Med 2000; 160: 526-34.

5. Razvi S, Ingoe LE, McMillan CV, Weaver JU. Health status in patients with sub-clinical hypothyroidism. Eur J Endocrinol 2005; 152:713-7.

6. Reuters    VS,    Teixeira Pde F, Vigario PS, Almeida CP, Buescu A, Ferreira    MM,    de Castro CL, Gold J, Vaisman M. Functional capacity and muscular abnormalities in subclinical hypothyroidism. Am J Med Sci 2009; 338:259-63.

7. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU 2007 The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in sub-clinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92:1715—1723

8. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86: 4860-6.

9. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A doubleblind, placebo-controlled trial. Ann Intern Med 1984; 101: 18-24.

10. Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen T.G. Neuro-psychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. J Clin Endocrinol Metab 2006; 91: 145-153.

11. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol (Oxf) 1988; 29: 63-75.

12. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev 2007; 3:CD003419.

13. Fowler PBS, Swale J, Andrews H. Hypercholesterolaemia in borderline hypothyroidism: Stage of premyxoedema. Lancet 1970; 2(7671): 488-491.

14. Bastenie PA, Vanhaelst L, Bonnyns M, Neve P, Staquet M. Preclinical hypothyroidism: a risk factor for coronary heart-disease. Lancet 1971;1(7692):203-4.

15. Dean JW, Fowler PBS. Exaggerated responsiveness to thyrotrophin releasing hormone: a risk factor in women with coronary artery disease. Br Med J (Clin Res Ed). 1985; 290: 1555-61.

16. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman, JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132: 270-278.

17. Imaizumi, M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, Ashizawa K, Yokoyama N, Maeda R, Nagataki S, Eguchi K. Risk for ischemic heart disease and allcause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89: 3365-3370.

18. Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165: 2467-2472.

19. Rodondi N, Newman AB, Vittinghoff, E, de Rekeneire N, Satterfield S, Harris TB, Bauer DC. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; 165: 2460-2466.

20. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295:1033-41.

21. Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgartner RN, Garry PJ. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey. Thyroid 2003; 13:595-600.

22. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Rodgers H, Tunbridge F, Young ET. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996; 6:155-60.

23. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001; 358: 861-865.

24. Gussekloo J, van Exel E, Craen AJM, Meinders AE, Frolich M, Westendorp RGJ. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004; 292: 2591-2599.

25. Boekholdt SM, Titan SM, Wiersinga WM, et al. Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. Clin Endocrinol (Oxf) 2010; 72: 404-410

26. Razvi S, Weaver JU, Vanderpump MP, Pearce SHS. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: re-analysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010; 95: 1734-40.

27. Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008; 125: 41-8.

28. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148: 832-45.

29. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159:329-41.

30. Razvi S, Shakoor A, Weaver JU, Vanderpump M, Pearce SH. The influence of age on ischeamic heart disease and mortality in subclinical hypothyroidism -a meta-analysis. J Clin Endocrinol Metab 2008; 93: 2998-3007

31. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP, Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gussekloo J; Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304:1365-74.

32. Thvilum M, Brandt F, Brix TH, Hegedus L. A review of the evidence for and against increased mortality in hypothyroidism. Nat Rev Endocrinol 2012 doi: 10.1038/nrendo.2012.29 [Epub ahead of print]

33. Forfar JC, Wathen CG, Todd WT, Bell GM, Hannan WJ, Muir AL, Toft AD. Left ventricular performance in subclinical hypothyroidism. Q J Med 1985; 57:857-65.

34. Foldes J, Istvanfy M, Halmagyi M, Varadi A, Gara A, Partos O. Hypothyroidism and the heart. Examination of left ventricular function in subclinical hypothyroidism. Acta Med Hung 1987; 44: 337-47.

35. Arem R, Rokey R, Kiefe C, Escalante DA, Rodriguez A. Cardiac systolic and diastolic function at rest and exercise in subclinical hypothyroidism: effect of thyroid hormone therapy. Thyroid 1996; 6: 397-402.

36. Biondi B, Fazio S, Palmieri EA, Carella C, Panza N, Cittadini A, Bone F, Lombardi G, Sacca L. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1999; 84: 2064-7.

37. Monzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C, Ferranini E. Effect of L-thyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebocontrolled study. J Clin Endocrinol Metab 2001; 86:1110-1115

38. Yazici M, Gorgulu S, Sertbas Y, Erbilen E, Albayrak S, Yildiz O, Uyan C. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. Int J Cardiol 2004; 95:135-43.

39. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000;10:665-79.

40. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, Salve tti D, Ferranini E, Monzani F. Impaired endotheliumdependent vasodilatation in subclinical hypothyroidism: beneficial effect of L-thyroxine therapy. J Clin Endocrinol Metab 2003; 88:3731-3737.

41. Shakoor SK, Aldibbiat A, Ingoe LE, Campbell SC, Sibal L, Shaw J, Home PD, Razvi S, Weaver JU. Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapy. J Clin Endocrinol Metab 2010 ; 95: 319-22.

42. Cai Y, Ren Y, Shi J. Blood pressure levels in patients with subclinical thyroid dysfunction: a meta-analysis of cross-sectional data. Hypertens Res 2011; 34: 1098-105.

43. Teixeira PF, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Melo BA, Buescu A, Costa AJ, Vaisman M. Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. Horm Metab Res 2008; 40: 50-5.

44. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85:2993-3001.

45. Gullu S, Sav H, Kamel N. Effects of L-thyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol 2005; 152:355-61.

46. TRUST study website. www.trustthyroidtrial.com

47. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract 1993; 43:107-9.

48. Okosieme OE, Belludi G, Spittle K, Kadiyala R, Richards J. Adequacy of thyroid hormone replacement in a general population. QJM 2011; 104: 395-401.

49. Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine Treatment of Subclinical Hypothyroidism, Fatal and Nonfatal Cardiovascular Events, and Mortality. Arch Intern Med 2012 [Epub ahead of print] PMID: 22529180

50. Pearce SH, Vaisman M, Wemeau JL. Management of subclinical hypothyroidism: The thyroidologists’ view. Eur Thyroid J 2012; 1: 45-50.

51. McDermott MT, Haugen BR, Lezotte DC, Seggelke S, Ridgway EC. Management practices among primary care physicians and thyroid specialists in the care of hypothyroid patients. Thyroid 2001; 11:757-64.

52. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007; 167: 1533-8.

53. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010; 95:E44-8.

54. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081- 125.

55. Vaidya B, Pearce SHS. Management of hypothyroidism in adults. BMJ 2008;337: 284-89.

56. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55-68